4-(3-硝基苯基磺酰)吗啉 | 91619-33-9

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-硝基苯基磺酰)吗啉
• 中文别名: 4-(3-硝基苯磺酰基)吗啉
• 英文名称: 4-<3-Nitro-benzol-sulfonyl-(1)>-morpholin
• 英文别名: 4-(3-nitrophenylsulfonyl)morpholine；4-(3-nitro-benzenesulfonyl)-morpholine；4-(3-nitrophenyl)sulfonylmorpholine
• CAS: 91619-33-9
• 化学式: C₁₀H₁₂N₂O₅S
• mdl: MFCD00622715
• 分子量: 272.282
• InChiKey: XCYXNNGNLAIXNM-UHFFFAOYSA-N

物化性质

• 熔点：
  173-174 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  450.9±55.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(3-Nitrophenylsulfonyl)morpholine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P302+P352: IF ON SKIN: Wash with soap and water
P321: Specific treatment (see on this label)
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(3-Nitrophenylsulfonyl)morpholine
Ingredient name:
CAS number: 91619-33-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H12N2O5S
Molecular weight: 272.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(3-硝基苯基磺酰)吗啉 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 2.0h， 生成 8-cyclopentyl-2-(3-(morpholinosulfonyl)phenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  提供异环化合物作为CDK4或CDK6或其他CDK抑制剂。这些化合物可能作为治疗疾病的治疗剂，特别是在肿瘤学方面可能具有特殊用途。

  公开号：

  WO2021003314A1
• 作为产物：
  描述：

  吗啉 、 3-硝基苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以88.3%的产率得到4-(3-硝基苯基磺酰)吗啉
  参考文献：
  名称：

  含唑磺胺类药物的合成及抗念珠菌活性

  摘要：

  已经合成了 25 种含有一个咪唑或三唑环，或两个咪唑或三唑环的苯磺酰胺，并作为抗念珠菌剂进行了评估。活性最强的化合物为 5c、6b、6c、6e 和 17b，根据临床分离株的不同，MIC 值为 4.55-24.39 mM。将咪唑与三唑衍生物进行比较并没有显示出对活性的明显影响。考虑到含有 N-苄基的化合物具有额外的芳环，它们也没有显示出明确的活性证据。二级磺胺类药物 5l、5m 和 5n 显示出与其亲脂性成正比的活性。N-芳基取代衍生物5j、5k、5l、5m、5n和6j的活性也与其亲脂性成正比。作为亲脂性改善的结果，卤化增强了活性。

  DOI：

  10.1002/ardp.200700125

文献信息

• [EN] DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS<br/>[FR] DIAMINO-PYRIMIDINES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE L'ANGIOGENESE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003074515A1

  公开（公告）日：2003-09-12

  Benzimidazole derivatives of formula (I) , which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. (I)

  本发明描述了公式(I)的苯并咪唑衍生物，它们作为TIE-2和/或VEGFR-2抑制剂是有用的。所描述的发明还包括制造这样的苯并咪唑衍生物的方法，以及使用它们在治疗增生性疾病中的方法。
• Diamino-pyrimidines and their use as angiogenesis inhibitors
  申请人：Chamberlain Dawes Stanley

  公开号：US20050234083A1

  公开（公告）日：2005-10-20

  Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了作为TIE-2和/或VEGFR-2抑制剂有用的苯并咪唑衍生物。所述发明还包括制备这种苯并咪唑衍生物的方法，以及将其用于治疗过度增殖性疾病的方法。
• Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis
  申请人：Cai Xiong Sui

  公开号：US20070043076A1

  公开（公告）日：2007-02-22

  The present invention is directed to substituted 2-arylmethylene-N-aryl-N′-aryl-malonamides and analogs thereof. The present invention also relates to the discovery that the compounds are activators of caspases and inducers of apoptosis. Therefore, the activators os caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的2-芳基亚甲基-N-芳基-N'-芳基-马隆酰胺及其类似物。本发明还涉及发现这些化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导各种临床情况下不受控制的异常细胞的生长和扩散。
• Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase
  作者：Sampath-Kumar Anandan、Richard D. Gless

  DOI：10.1016/j.bmcl.2010.03.074

  日期：2010.5

  The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N'-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment. (C) 2010 Elsevier Ltd. All rights reserved.
• [EN] SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS<br/>[FR] MALONAMIDES 2-ARYLMETHYLENE-N-ARYL-N'-ARYL SUBSTITUES ET LEURS ANALOGUES UTILES COMME ACTIVATEURS DES CASPASES ET INDUCTEURS DE L'APOPTOSE
  申请人：CYTOVIA INC

  公开号：WO2005037196A3

  公开（公告）日：2005-10-13